<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336888">
  <stage>Registered</stage>
  <submitdate>4/05/2011</submitdate>
  <approvaldate>12/05/2011</approvaldate>
  <actrnumber>ACTRN12611000498998</actrnumber>
  <trial_identification>
    <studytitle>Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of adults with atypical hemolytic-uremic syndrome</studytitle>
    <scientifictitle>Adult patients testing eculizumab for atypical hemolytic-uremic syndrome for safety and efficacy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ClinicalTrials.gov reference NCT01194973</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atypical Hemolytic-Uremic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Eculizumab 900mg administered intravenously weekly for  4 weeks via infusion over 30 minutes then 1200mg intravenous infusion every two weeks for 26 weeks with the possibility of continued treatment for up to 2 years or until marketing approval.</interventions>
    <comparator>None. This is an open label study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with complete TMA response</outcome>
      <timepoint>endpoints to be assessed after 26 weeks treatment based on blood results from routine blood testing.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>duration of complete TMA response</outcome>
      <timepoint>endpoints to be assessed after 26 weeks treatment based on blood results from routine blood testing.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients must be willing to give written informed consent.
Patients must be over 18 years of age with a diagnosis of atyipcal hemolytic-uremic syndrome.
Patients exhibit thrombocytopenia, hemolysis and elevated serum creatinine.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Chronic dialysis.
Prior eculizumab use or hypersensitivity to eculizumab, to murine proteins or to one of the excipients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Once a patient has been screened and meets all eligibility criteria and has signed the consent form, they can be enrolled in the study. This is an open label study so all patients enrolled will be given active study drug.</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alexion Pharmaceuticals Australasia Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Alexion Pharmaceuticals Australasia Pty Ltd</fundingname>
      <fundingaddress>Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Atypical hemolytic-uremic syndrome is a serious, life-threatening rare and chronic disease believed to be caused by genetic mutations. Current treatment for the disease is inadequate. 
Due to the uncontrolled complement activation seen in aHUS patients and the previously shown activity of eculizumab to selectively inhibit terminal complement activation, it has been decided to look in to the use of eculizumab in the treatment of serverely affected aHUS patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Level 6 East, Main Building
300 Grattan Street
The Royal Melbourne Hospital  
Parkville VIC  3050</ethicaddress>
      <ethicapprovaldate>11/07/2011</ethicapprovaldate>
      <hrec>2011.092</hrec>
      <ethicsubmitdate>29/04/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jean Young</name>
      <address>Medical Affairs Manager
Alexion Pharmaceuticals Australasia Pty Ltd
Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>YoungJ@alxn.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Nicola Cowlishaw</name>
      <address>Regional Monitor
Alexion Pharmaceuticals Australasia Pty Ltd
Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>CowlishawN@alxn.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Nicola Cowlishaw</name>
      <address>Regional Monitor
Alexion Pharmaceuticals Australasia Pty Ltd
Suites 226-227, 117 Old Pittwater Road
Brookvale NSW 2100</address>
      <phone>+61 2 9091 0500</phone>
      <fax>+61 2 9091 0511</fax>
      <email>CowlishawN@alxn.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>